

# MINA Antibody

Catalog # ASC11072

## **Product Information**

**Application** WB, IF, E, IHC-P

Primary Accession Q8IUF8

Other Accession <u>NP\_694822</u>, <u>110227621</u>

**Reactivity** Human, Mouse

Host Rabbit
Clonality Polyclonal
Isotype IgG
Calculated MW 52800
Concentration (mg/ml) 1 mg/mL
Conjugate Unconjugated

**Application Notes** MINA antibody can be used for detection of MINA by Western blot at 1 - 2

□g/mL. Antibody can also be used for immunohistochemistry starting at 5

□g/mL. For immunofluorescence start at 20 □g/mL.

#### **Additional Information**

**Gene ID** 84864

Other Names Bifunctional lysine-specific demethylase and histidyl-hydroxylase MINA,

1.14.11.-, 60S ribosomal protein L27a histidine hydroxylase, Histone lysine demethylase MINA, MYC-induced nuclear antigen, Mineral dust-induced gene protein, Nucleolar protein 52, Ribosomal oxygenase MINA, ROX, MINA

(HGNC:19441)

Target/Specificity MINA;

**Reconstitution & Storage** MINA antibody can be stored at 4°C for three months and -20°C, stable for up

to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high

temperatures.

**Precautions** MINA Antibody is for research use only and not for use in diagnostic or

therapeutic procedures.

### **Protein Information**

Name RIOX2 ( HGNC:19441)

**Function** Oxygenase that can act as both a histone lysine demethylase and a

ribosomal histidine hydroxylase. Is involved in the demethylation of trimethylated 'Lys-9' on histone H3 (H3K9me3), leading to an increase in ribosomal RNA expression. Also catalyzes the hydroxylation of 60S ribosomal protein L27a on 'His-39'. May play an important role in cell growth and survival. May be involved in ribosome biogenesis, most likely during the

assembly process of pre-ribosomal particles.

**Cellular Location** Nucleus. Nucleus, nucleolus

**Tissue Location** Expressed in liver, skeletal muscle, heart, pancreas, and placenta. Not

detected in brain, lung or kidney Expressed in several lung cancer tissues, but is barely detected in the adjacent non-cancerous tissues. Also highly

expressed in several esophageal squamous cell carcinoma (ESCC), and colon

cancer tissues, and in various cancer cell lines.

# **Background**

MINA Antibody: MINA is nuclear localized, myc-inducible protein that is thought to play a role in mammalian cell proliferation. Treatment of cancer cells lines such as the colon cancer cell line SW680 with siRNA against MINA inhibits cell growth, demonstrating that MINA may be a potential therapeutic target. MINA regulates several genes related to cell adhesion and metabolism that have also been shown to be regulated by c-Myc, but also regulates other genes whose expression are not modulated by c-Myc such as EGFR, IL-6 and HGF. MINA has also been found to act as a repressor to IL-4 expression in T cells, indicating that it may also play a role in T cell differentiation and genetic variation in T helper type 2 bias.


#### References

Tsuneoka M, Kody Y, Soejima M, et al. A novel myc target gene, mina53, that is involved in cell proliferation. J. Biol. Chem.2002; 277:35450-9.


Teye K, Tsuneoka M, Arima N, et al. Increased expression of a Myc target gene Mina53 in human colon cancer. Am. J. Pathol.2004; 164:205-16.

Komiya K, Sueoka-Aragane N, Sato A, et al. Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells. J. Cancer Res. Clin. Oncol.2010; 136:465-73. Okamoto M, Van Stry M, Chung L, et al. Mina, an IL4 repressor, controls T helper type 2 bias. Nat. Immunol.2009; 10:872-9.


# **Images**



Western blot analysis of MINA in human heart tissue lysate with MINA antibody at (A) 1 and (B) 2 µg/mL.



Immunohistochemistry of MINA in mouse heart tissue with MINA antibody at 5 µg/mL.



Immunofluorescence of MINA in mouse heart tissue with MINA antibody at 20  $\mu g/mL$ .

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.